 |
Photo = Yonhap news |
[Alpha Biz= Kim Jisun] GC Biopharma announced on Tuesday that its U.S. subsidiary, Curevo, has successfully raised $110 million (approximately 158.8 billion KRW) in Series B funding for the development of its shingles vaccine.
Curevo is developing the shingles vaccine "Amezosbatein" (project name CRV-101). The funding round was led by Medici, a European life sciences-focused venture capital firm with extensive experience in vaccine investments, along with participation from Obimed, HBM Healthcare Investors, and Sanofi Ventures.
The successful fundraising was made possible by active follow-up investments from existing investors, including GC Biopharma, as well as the addition of several new investors.
Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)
